Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 11/20 | 0.46 |
| ▸ | GAA | P10253 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561254 | 1.00 | NOX1 (0.54) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL14294534 | 1.00 | NOX1 (0.54) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL13109406 | 0.85 | NOX1 (0.62) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL16111930 | 0.85 | NOX1 (0.62) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL16111932 | 0.85 | NOX1 (0.62) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL680401 | 0.78 | GAA (0.45) | MAPTGAAKMT2AMEN1RAB9A | |
| SCHEMBL7527344 | 0.78 | MAPT (0.47) | MAPTGAAKMT2AMEN1RAB9A | |
| SCHEMBL680400 | 0.78 | GAA (0.45) | MAPTGAAKMT2AMEN1RAB9A | |
| SCHEMBL1876868 | 0.77 | NOX1 (0.54) | NOX1MAPTGAAKMT2AMEN1 | |
| SCHEMBL1876865 | 0.77 | NOX1 (0.54) | NOX1MAPTGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-2604597-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF INHIBITOR OF PHOSPHODIESTERASE 10A | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9150588-B2 | Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2604597-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-4016263-A | BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137675-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | PDE3A, PDE2A, PDE5A | NOX1 41/4885MAPT 3481/4885GAA 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.